QUANTITY LIMIT CRITERIA

DRUG CLASS

[ANTIVIRAL FOR THE TREATMENT OF COVID-19]

BRAND NAME (generic)

PAXLOVID

(nirmatrelvir [PF-07321332] tablets and ritonavir tablets)

Status: CVS Caremark Criteria Type: Quantity Limit

POLICY

<u>USES</u>

Emergency Use Authorization (EUA) for the treatment of mild-to-moderate COVID-19 in adults and pediatric patients (12 years of age and older weighing at least 40 kg) with positive results of direct SARS-CoV-2 viral testing, and who are at high risk for progression to severe COVID-19, including hospitalization or death.

REFERENCES

1) Paxlovid [Emergency Use Authorization Fact Sheet for Health Care Providers]. New York, NY: Pfizer; December 22, 2021.

LIMIT CRITERIA

<u>Drug</u>

Limit*

PAXLOVID (nirmatrelvir [PF-07321332] tablets and ritonavir tablets)

30 tablets (1 carton containing 30 tablets divided in 5 daily-dose blister cards, with each daily-dose blister card containing 4 tablets of nirmatrelvir [PF-07321332] 150mg and 2 tablets of ritonavir 100mg and indicates which tablets need to be taken in the morning and evening for a total of 10 doses) / 30 days

* These drugs are for short-term acute use.

Paxlovid Limit Policy 5099-H 12-2021.docx

©2021 CVS Caremark. All rights reserved.

This document contains confidential and proprietary information of CVS Caremark and cannot be reproduced, distributed or printed without written permission from CVS Caremark. This document contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers not affiliated with CVS Caremark.